CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.
Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
与许多其他恶性肿瘤不同，过去半个世纪里，上皮性卵巢癌女性患者的总生存期仅有小幅改善。本文从妇科肿瘤医生回顾历史和学术编辑展望未来两个角度，阐述对卵巢癌的看法：从1809年的外科治疗起步，延伸至当前及未来的基因组学、手术进展和精准治疗。本期专题介绍了卵巢癌诊断相关因素：（1）用于术前评估原发及转移性卵巢肿瘤的标志物；（2）超声检查中卵巢恶性肿瘤存在盆腔积液的实例；（3）年龄、绝经状态和体型对卵巢显像的影响；（4）在CA125未能提供有效信息时，OVA1检测卵巢癌的能力；（5）通过组织染色检测细胞黏附分子的肿瘤特异性改变；（6）结合IOTA简易规则和CA125构建的高鉴别能力卵巢癌模型；（7）卵巢低级别浆液性癌综述；以及（8）卵巢癌肉瘤的综合病例报告。
Unlike many other malignancies, overall survival for women with epithelial ovarian cancer has improved only modestly over the last half-century. The perspectives presented here detail the views of a gynecologic oncologist looking back and the view of the academic editor looking forward. Surgical beginnings in 1809 are merged with genomics, surgical advances, and precision therapy at present and for the future.
Presentations in this special issue focus on factors related to the diagnosis of ovarian cancer: (1) markers for the preoperative assessment of primary and metastatic ovarian tumors, (2) demonstrations of the presence of pelvic fluid in ultrasound studies of ovarian malignancies, (3) the effects of age, menopausal status, and body habitus on ovarian visualization, (4) the ability of OVA1 to detect ovarian cancers when Ca125 was not informative, (5) the detection of tumor-specific changes in cell adhesion molecules by tissue-based staining, (6) presentation of a high discrimination model for ovarian cancer using IOTA Simple Rules and CA125, (7) review of low-grade serous carcinoma of the ovary, and (8) a comprehensive case report on ovarian carcinosarcoma.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
